NCT05337878View on ClinicalTrials.gov

A Study to Assess Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Pelacarsen (ISIS 681257) in Healthy Japanese Participants

PHASE1CompletedINTERVENTIONAL
Enrollment

29

Participants

Timeline

Start Date

October 15, 2018

Primary Completion Date

December 18, 2019

Study Completion Date

December 18, 2019

Conditions
Healthy Participants
Interventions
DRUG

Placebo

Pelacarsen-matching placebo administered by SC injection.

DRUG

Pelacarsen

Pelacarsen administered by SC injection.

Trial Locations (1)

91206

Parexel International, Glendale

Sponsors
All Listed Sponsors
lead

Ionis Pharmaceuticals, Inc.

INDUSTRY